Trial Information

Summary: Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

The overall aim of this study is to assess the efficacy and safety of AS1411, over a range of doses, when combined with cytarabine, in the treatment of patients with primary refractory or relapsed acute myeloid leukemia (AML).

Patient Inclusion Criteria

• Primary refractory or relapsed AML
• Confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification (Vardiman 2002)
• Aged at least 18 years

Patient Exclusion Criteria

• Initial diagnosis of acute promyelocytic leukemia as defined by French-American-British criteria (Bennett 1976)
• Patient in blast crisis stage of chronic myeloid leukemia
• Received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
• Interval of <6 months between first onset of last complete remission and current relapse
• Those with primary refractory leukemia who have received more than three previous induction cycles
• Relapsed patients who have received more than three previous treatment regimens

If you would like to learn more about participating in this study, please send an e-mail message using the form below.